Four AHA patients without a baseline antiporcine FVIII inhibitor who received rpFVIII treatment developed a de novo inhibitor with a median titer of 1.5 BU/mL (range, 0.75-12) after a median of 21 days (range, 9-134). Here, F8 is linked to autoimmune hemolytic anemia.